Clear Harbor Asset Management LLC Increases Stock Position in IQVIA Holdings Inc. $IQV

Clear Harbor Asset Management LLC boosted its position in IQVIA Holdings Inc. (NYSE:IQV) by 33.0% during the fourth quarter, Holdings Channel.com reports. The fund owned 14,835 shares of the medical research company’s stock after acquiring an additional 3,677 shares during the period. Clear Harbor Asset Management LLC’s holdings in IQVIA were worth $3,344,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Ameliora Wealth Management Ltd. purchased a new stake in shares of IQVIA during the fourth quarter worth about $25,000. Physician Wealth Advisors Inc. raised its position in IQVIA by 1,340.0% during the 3rd quarter. Physician Wealth Advisors Inc. now owns 144 shares of the medical research company’s stock valued at $27,000 after purchasing an additional 134 shares during the last quarter. International Assets Investment Management LLC bought a new position in IQVIA during the 4th quarter valued at approximately $27,000. Westside Investment Management Inc. lifted its holdings in IQVIA by 219.6% in the 3rd quarter. Westside Investment Management Inc. now owns 147 shares of the medical research company’s stock worth $30,000 after buying an additional 101 shares during the period. Finally, Measured Wealth Private Client Group LLC bought a new stake in shares of IQVIA in the 3rd quarter worth approximately $30,000. 89.62% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of equities analysts recently commented on IQV shares. Royal Bank Of Canada initiated coverage on IQVIA in a report on Tuesday, March 3rd. They set an “outperform” rating and a $221.00 target price for the company. Stifel Nicolaus cut their price target on shares of IQVIA from $273.00 to $220.00 and set a “buy” rating on the stock in a report on Friday, February 6th. JPMorgan Chase & Co. reduced their price objective on shares of IQVIA from $255.00 to $225.00 and set an “overweight” rating on the stock in a research report on Friday, February 6th. Truist Financial decreased their price objective on shares of IQVIA from $290.00 to $245.00 and set a “buy” rating for the company in a report on Thursday, February 19th. Finally, Jefferies Financial Group cut their target price on shares of IQVIA from $270.00 to $255.00 and set a “buy” rating on the stock in a research note on Friday, February 6th. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $225.69.

IQVIA Price Performance

IQV opened at $182.03 on Monday. The company has a current ratio of 0.75, a quick ratio of 0.75 and a debt-to-equity ratio of 2.20. The company has a market cap of $30.38 billion, a price-to-earnings ratio of 22.56, a price-to-earnings-growth ratio of 1.74 and a beta of 1.21. The stock has a fifty day simple moving average of $170.34 and a two-hundred day simple moving average of $196.05. IQVIA Holdings Inc. has a 12-month low of $136.41 and a 12-month high of $247.04.

IQVIA (NYSE:IQV) last announced its earnings results on Tuesday, May 5th. The medical research company reported $2.90 EPS for the quarter, beating analysts’ consensus estimates of $2.83 by $0.07. The firm had revenue of $4.15 billion for the quarter, compared to analysts’ expectations of $4.10 billion. IQVIA had a net margin of 8.33% and a return on equity of 30.50%. The company’s quarterly revenue was up 8.4% on a year-over-year basis. During the same quarter in the previous year, the business posted $2.70 EPS. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. Research analysts predict that IQVIA Holdings Inc. will post 11.57 earnings per share for the current fiscal year.

IQVIA declared that its Board of Directors has authorized a share buyback plan on Thursday, May 7th that allows the company to buyback $2.00 billion in shares. This buyback authorization allows the medical research company to buy up to 6.8% of its shares through open market purchases. Shares buyback plans are usually a sign that the company’s board believes its shares are undervalued.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.